Vectura Group plc Vectura Group appoints New Chief Executive Officer (3925R)
29 Ottobre 2019 - 8:00AM
UK Regulatory
TIDMVEC
RNS Number : 3925R
Vectura Group plc
29 October 2019
Vectura Group appoints New Chief Executive Officer
Will Downie joins from Catalent Inc., one of the world's largest
Contract Development and Manufacturing Organisations
Chippenham, UK - 29 October 2019: Vectura Group plc (LSE: VEC)
("Vectura", the "Group", or the "Company"), is pleased to announce
the appointment of Will Downie as CEO and Executive Director of the
Company with effect from 7(th) November 2019.
Prior to joining Vectura, Will spent ten years as the Senior
Vice President, Global Sales and Marketing at Catalent Inc., one of
the world's largest Contract Development and Manufacturing
Organisations (CDMO).
In his role at Catalent, Will led the commercial effort and had
responsibility for global sales, marketing and commercial
operations activities. During his tenure, he developed an
outstanding track record in helping drive the long-term growth of
the company as well as positioning Catalent as one of the leading
brands in the pharmaceutical services space. He has a deep
understanding of the development and advanced drug delivery market
and has amassed significant experience in driving sustained
long-term results, as well as building performance-focused
organisations and meeting customer needs on a global scale.
Prior to Catalent, Will held positions as Vice President &
General Manager, Global Molecular Imaging at GE Healthcare, Vice
President Sales EMEA at Amersham Health and Director of Business
Development and Commercial Operations at Quintiles Innovex UK
Limited. In his early career, he worked in a range of sales and
marketing management positions at both Sanofi and Merck &
Co.
Bruno Angelici, Chairman, commented: "I am very pleased to
welcome Will Downie as Vectura's new CEO. He brings a wealth of
relevant experience which will help Vectura to grow and deliver on
its new strategic focus as a leading inhaled CDMO business.
"I would like to thank Paul Fry for the significant work he has
done since stepping into the Interim Chief Executive role and
driving the change necessary for Vectura to become a leading player
in the inhaled CDMO space. Paul will resume his responsibilities as
Chief Financial Officer from 7(th) November."
Will Downie commented: "I am delighted to have accepted the role
of CEO of Vectura and to have the opportunity to expand and build
on its reputation as an inhalation device and formulation
specialist. I am looking forward to driving the new business
strategy and ensuring the Company achieves its long-term goal of
becoming a world class CDMO organisation in the inhalation
space."
There are no additional details to disclose under Listing Rule
9.6.13 (1) to (6) in respect of the appointment of Will Downie.
-Ends-
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / David Daley +44 (0)20 3709 5700
About Vectura
Vectura is a provider of innovative inhaled drug delivery
solutions that enable partners to bring their medicines to
patients. With differentiated proprietary technology and
pharmaceutical development expertise, Vectura is one of the few
companies globally with the device, formulation and development
capabilities to deliver a broad range of complex inhaled
therapies.
Vectura has ten key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
For further information, please visit Vectura's website at
www.vectura.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKMMZGLRMGLZM
(END) Dow Jones Newswires
October 29, 2019 03:00 ET (07:00 GMT)
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Apr 2023 a Apr 2024